Brief: Quantum Biopharma Announces Appointment Of Principal Investigator For Planned Phase 2 Clinical Trial Of Lucid-21-302 (Lucid-MS) In Multiple Sclerosis
26/03/2026 12:59
Quantum Biopharma Ltd QNTM.CD: QUANTUM BIOPHARMA ANNOUNCES APPOINTMENT OF PRINCIPAL INVESTIGATOR FOR PLANNED PHASE 2 CLINICAL TRIAL OF LUCID-21-302 (LUCID-MS) IN MULTIPLE SCLEROSIS Source text: ID:nGNX5GJLdk Further company coverage: QNTM.CD